Wells Fargo lowered the firm’s price target on Voyager Therapeutics (VYGR) to $12 from $14 and keeps an Overweight rating on the shares. With ...

Wedbush reiterated their outperform rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a report ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Voyager Therapeutics said it will assess alternate payloads related to its gene therapeutic program related to a form of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

Voyager Therapeutics Inc . (NASDAQ:VYGR) stock has reached a 52-week low, touching down at $4.12. According to InvestingPro analysis, the stock's RSI indicates oversold territory, while the company ...

Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million.

In a recent transaction, Alfred Sandrock, President and CEO of Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotech company with a market capitalization of $240 million and strong financial health ...

Investors might want to bet on Voyager Therapeutics (VYGR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will ...